Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CPIX, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Conivaptan Hydrochloride FDA approved Feb 2007 · Vaprisol |
Hyponatremia | Phase 3 · NCT01451411 | Terminated |
| Ascorbic Acid | Autism | N/A · NCT00889538 | Completed |
| Ketorolac | Pain | Phase 4 · NCT01901393 | Completed |
| Ketorolac Tromethamine | Arthroscopic Knee Surgery | Phase 4 · NCT01650519 | Completed |
| Ibuprofen | Arthroscopic Knee Surgery | Phase 4 · NCT01650519 | Completed |
| Telavancin | Subarachnoid Hemorrhage, Aneurysmal | Phase 4 · NCT06119061 | Recruiting |
| Acetylcysteine | Acetaminophen Overdose | Phase 3 · NCT01118663 | Terminated |
| Vancomycin | Bacteremia | Phase 3 · NCT02208063 | Terminated |
| 135 grams of Crystalline Lactulose | Colonoscopy Preparation | Phase 2 · NCT02123017 | Completed |
| Squalamine Lactate Ophthalmic Solution, 0.2% | Retinal Vein Occlusion | Phase 1/2 · NCT02614937 | Completed |
| Split dose preparation | Colonoscopy Preparation | Phase 2 · NCT01887470 | Completed |
| Ifetroban | Scleroderma, Diffuse | Phase 2 · NCT02682511 | Active not recruiting |
| Vancomycin or antistaphylococcal penicillin | Infections, Gram-Positive Bacterial | Phase 2 · NCT00061633 | Completed |
| Ifetroban Sodium | Idiopathic Pulmonary Fibrosis | Phase 2 · NCT05571059 | Recruiting |
| Full dose preparation | Colonoscopy Preparation | Phase 2 · NCT01887470 | Completed |
| Crystalline Lactulose | Colonoscopy | Phase 2 · NCT01650870 | Completed |
Also used in these trials (approved or third-party drugs, not CPIX's own candidates): Kojic Acidskin Lightening, Acetaminophen, Indomethacin, Nafcillin Sodium, Daptomycin, Cefazolin, Ranibizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CPIX holds $3.9M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CPIX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| A J Kazimi Chairman and CEO, Director, 10% owner · +568,000 options |
Insider | 5,695,310 | 37.98% | 2026-03-16 |
| Kenneth Krogulski Director |
Insider | 302,338 | 2.02% | 2026-03-18 |
| Joseph C Galante Director |
Insider | 63,656 | 0.42% | 2026-03-18 |
| James Jones Director |
Insider | 46,863 | 0.31% | 2026-03-18 |
| Caroline Young Director |
Insider | 35,109 | 0.23% | 2026-03-18 |
| Martin S JR Brown Director |
Insider | 10,300 | 0.07% | 2026-03-18 |
Share count 14,995,547 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CPIX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →